|
Basic Characteristics of Mutations
|
|
Mutation Site
|
V173L |
|
Mutation Site Sentence
|
Prolonged LAM therapy is associated with the emergence of LAM-resistant mutations, from 24% in 1 year to 70% in 5 years. Three mutations associated with LAM resistance have been mostly described: rtM204V/I in C domain, rtV173L and rtL180M in B domain. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B, Chronic
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
Lamivudine(LAM) |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
33758517
|
|
Title
|
The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report
|
|
Author
|
Li J,Zhang D,Zhang X
|
|
Journal
|
Infection and drug resistance
|
|
Journal Info
|
2021 Mar 15;14:1013-1017
|
|
Abstract
|
Tenofovir disoproxil fumarate (TDF) is recommended as first-line agents in chronic hepatitis B (CHB) patients for its high antiviral effects and high barrier to resistance. It is controversial whether the rtA194T mutation truly confers resistance against TDF. We present here a 62-year-old CHB patient who occurred rtL180M, rtM204V and rtA194T mutants after lamivudine (LAM) monotherapy for 9 years. TDF was introduced in replacement of LAM and led to Hepatitis B Virus (HBV) DNA undetectable in 1 month, maintained in the follow up of 52 weeks. These observations suggest that rtA194T mutation emerges under LAM monotherapy and remains sensitive to TDF.
|
|
Sequence Data
|
-
|